Single-dose and steady-state effects of controlled-release salbutamol on drug level and airflow obstruction in patients with asthma.
Oral medication remains the mainstay of treatment for many asthmatics. We compared the single dose and steady-state effects of twice daily 4 mg and 8 mg controlled-release salbutamol (CRS) on plasma salbutamol and FEV1 in 10 asthmatic patients in a double-blind, double-dummy, cross-over study. On 5 separate days, one week apart, we measured FEV1 and plasma salbutamol hourly for 12 hours after a single dose and, after twice daily doses (4 mg, 8 mg or placebo CRS) for one week. Controlled-release salbutamol showed controlled release properties and dose effect for the two doses. At steady-state, it provided relatively constant plasma levels for 12 hours. Significant and similar bronchodilatation occurred after both 4 mg and 8 mg CRS taken either as a single dose or a steady-state regime.